Continuous inhalation of ipratropium bromide for acute asthma refractory to β2-agonist treatment

Journal of Pediatric Pharmacology and Therapeutics

Volumn 20, Issue 1, 2015, Pages 66-69

  Koumbourlis, Anastassios C ^a   Mastropietro, Christopher ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Asthma; Bronchodilator; Continuous nebulization; Ipratropium bromide; Severe asthma; 2 agonists

Indexed keywords

EID: 85052417980     PISSN: 15516776     EISSN: 2331348X     Source Type: Journal    
DOI: 10.5863/1551-6776-20.1.66     Document Type: Article

References (20)

1. Yim RP, Koumbourlis AC. Tolerance & resistance to β2-agonist bronchodilators. Paediatr Respir Rev. 2013;14(3):195-198.
2. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336(8728):1391-1396.
3. Spitzer WO, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326(8):501-506.
4. Walters EH, Walters J. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev. 2000;(4):CD001285.
5. Cooper PR, Panettieri RA Jr. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy ClinI Immunol.2008;122(4):734-740.
6. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med.1995;152(3):838-860.
7. Hadcock JR, Wang HY, Malbon CC. Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. J Biol Chem. 1989;264(33):19928-19933.
8. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992;327(17):1204-1208.
9. Turner SW. Genetic predictors of response to therapy in childhood asthma. Mol Diagn Ther. 2009;13(2):127-135.
10. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet.2004;364(9444):1505-1512.
11. Giubergia V, Gravina LP, Castanos C et al. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol. 2008;43(5):421-425.
12. Lee MY, Cheng SN, Chen SJ et al. Polymorphisms of the beta2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer. Pediatr Neonatol.2011;52(1):18-23.
13. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry.1994;33(32):9414-9419.
14. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta 2-adreno-ceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet.1995;345(8959):1213-1214.
15. Taylor DR, Drazen JM, Herbison GP et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55(9):762-767.[PMC free article]
16. Teoh L, Cates CJ, Hurwitz M et al. Anticholinergic therapy for acute asthma in children. Cochrane Database Syst Rev. 2012;(4):CD003797.
17. Craven D, Kercsmar CM, Myers TR et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr. 2001;138(1):51-58.
18. Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med. 2001;155(12):1329-1334.
19. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J Antimicrob Chemother. 2005;55(1):10-21.
20. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microb Rev. 2010;23(3):590-615.